The Wits Vaccines and Infectious Diseases Analytics Research Unit, which runs the ChAdOx1 nCoV-19 vaccine trial in South Africa, has announced results
In an analysis, submitted as a pre-print prior to peer-review publication, a two-dose regimen of the ChAdOx1 nCoV-19 vaccine provides minimal protection against mild-moderate COVID-19 infection from the… read more.
